Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2011 • 7,390 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 • 1,729 citations

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 • 1,404 citations

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 • 1,252 citations

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 • 1,139 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 • 976 citations

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

2011 • 964 citations

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 • 812 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 • 756 citations

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

2010 • 703 citations

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

2006 • 636 citations

MEK1 mutations confer resistance to MEK and B-RAF inhibition

2009 • 622 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

2008 • 569 citations

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

2009 • 551 citations

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

2009 • 546 citations

B-RAF is a therapeutic target in melanoma

2004 • 435 citations

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

2005 • 350 citations

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

2004 • 281 citations

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

2007 • 280 citations

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

2010 • 278 citations

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

2008 • 252 citations

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

2007 • 247 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

2010 • 244 citations

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

2010 • 232 citations

Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models

2006 • 229 citations

Ipilimumab: controversies in its development, utility and autoimmune adverse events

2009 • 223 citations

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

1997 • 197 citations

Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

2007 • 186 citations

BRAF Signaling and Targeted Therapies in Melanoma

2009 • 184 citations

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

2003 • 166 citations

Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway

2008 • 164 citations

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

2011 • 152 citations

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

2011 • 133 citations

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

2008 • 131 citations

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

2011 • 123 citations

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

2011 • 121 citations

Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis

2009 • 120 citations

Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway

2003 • 117 citations

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

2010 • 108 citations

Implantation of neural stem cells embedded in hyaluronic acid and collagen composite conduit promotes regeneration in a rabbit facial nerve injury model

2008 • 92 citations

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

2005 • 91 citations

CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues

2008 • 58 citations

Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

2008 • 47 citations

An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy

2008 • 36 citations

Novel targets in solid tumors: MEK inhibitors.

2006 • 33 citations

Ipilimumab: a promising immunotherapy for melanoma.

2010 • 32 citations

A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).

2011 • 23 citations

Improving outcomes in early-stage breast cancer.

2010 • 22 citations

Frequency of mutations associated with targeted therapy in malignant melanoma patients.

2011 • 21 citations

Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma.

2011 • 16 citations

Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010

2010 • 13 citations

Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).

2011 • 6 citations